Pluri Inc. (PLUR): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução da medicina regenerativa, a Pluri Inc. (PLUR) surge como uma empresa inovadora de biotecnologia pronta para revolucionar os paradigmas de tratamento neurológico. Ao alavancar tecnologias avançadas de células -tronco e pioneiras abordagens inovadoras de terapia celular, o Pluri não está apenas desenvolvendo tratamentos, mas reimaginando fundamentalmente como abordamos distúrbios neurológicos complexos. Sua tela de modelo de negócios meticulosamente criada revela um plano estratégico que entrelaça pesquisas científicas de ponta, parcerias colaborativas e soluções médicas transformadoras projetadas para enfrentar desafios de saúde não atendidos com precisão e potencial sem precedentes.

Pluri Inc. (PLUR) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa de terapia celular

A partir de 2024, a Pluri Inc. estabeleceu parcerias de pesquisa com as seguintes instituições acadêmicas e de pesquisa:

Instituição	Foco de colaboração	Ano estabelecido
Universidade da Califórnia, São Francisco	Pesquisa de células -tronco	2022
Instituto de Células Estrem Harvard	Medicina Regenerativa	2023

Parcerias com empresas de biotecnologia e farmacêutica

A Pluri Inc. desenvolveu alianças estratégicas com as seguintes entidades biotecnologia e farmacêutica:

• Biontech SE - Pesquisa colaborativa em tecnologias de terapia celular
• Novartis AG - Desenvolvimento conjunto de soluções de medicina regenerativa
• Gilead Sciences, Inc. - Integração da plataforma de terapia celular

Alianças com fabricantes de dispositivos médicos

Parceiro de dispositivos médicos	Tipo de colaboração	Valor do contrato
Medtronic plc	Integração de dispositivos de terapia celular	US $ 5,2 milhões
Stryker Corporation	Tecnologia de Medicina Regenerativa	US $ 3,7 milhões

Potenciais joint ventures no desenvolvimento da medicina regenerativa

Status de exploração atual da joint venture:

• Pendente da joint venture com a clínica Mayo - pesquisa de regeneração neurológica
• Discussões preliminares com a Universidade Johns Hopkins - terapia de células cardíacas
• Parceria exploratória com Stanford Medicine - Engenharia de Cells Imune

Pluri Inc. (PLUR) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de células -tronco

A partir de 2024, a Pluri Inc. alocou US $ 12,4 milhões para os esforços de pesquisa e desenvolvimento de células -tronco.

Área de pesquisa	Investimento anual	Pessoal de pesquisa
Tecnologia de células -tronco pluripotentes	US $ 5,6 milhões	37 pesquisadores
Técnicas de diferenciação celular	US $ 3,2 milhões	22 cientistas

Inovação em terapia celular avançada

A Pluri Inc. investiu US $ 8,7 milhões em inovação tecnológica durante 2024.

• Desenvolvido 4 novas plataformas de terapia celular
• Arquivou 6 novos pedidos de patente
• Mantido 12 projetos de desenvolvimento de tecnologia ativa

Gerenciamento e execução de ensaios clínicos

O orçamento de ensaios clínicos para 2024 foi de US $ 15,3 milhões.

Fase de teste	Número de ensaios	Orçamento estimado
Fase I.	3 ensaios	US $ 4,2 milhões
Fase II	2 ensaios	US $ 6,8 milhões
Fase III	1 Trial	US $ 4,3 milhões

Criação e proteção de propriedade intelectual

A Pluri Inc. gastou US $ 3,9 milhões em estratégias de propriedade intelectual em 2024.

• Total de patentes ativas: 37
• Pedidos de patente arquivados: 8
• Cobertura de patente geográfica: 12 países

Desenvolvimento terapêutico de produtos para doenças neurodegenerativas

Investimento de desenvolvimento de produtos: US $ 10,6 milhões em 2024.

Foco da doença	Estágio de desenvolvimento	Investimento em pesquisa
Doença de Parkinson	Pré-clínico	US $ 4,2 milhões
Doença de Alzheimer	Fase I.	US $ 3,7 milhões
Terapia com ALS	Exploratório	US $ 2,7 milhões

Pluri Inc. (PLUR) - Modelo de negócios: Recursos -chave

Tecnologias avançadas de manipulação celular

A Pluri Inc. mantém 3 Plataformas de manipulação celular proprietária central A partir de 2024, com recursos tecnológicos específicos:

Plataforma de tecnologia	Capacidade específica	Status de patente
Cellegen ™	Engenharia de células -tronco pluripotentes	4 patentes registradas
Neuroplex ™	Diferenciação de células neurais	2 patentes pendentes
Cardiosync ™	Regeneração do tecido cardíaco	3 patentes concedidas

Plataformas proprietárias de pesquisa de células -tronco

A infraestrutura de pesquisa inclui:

• 2 laboratórios dedicados de pesquisa de células -tronco
• Equipamento avançado de sequenciamento genômico
• Investimento total de infraestrutura de pesquisa: US $ 12,4 milhões

Equipe de pesquisa científica de alta qualificação

Composição da equipe	Número	Nível de qualificação
Pesquisadores de doutorado	24	Biologia de células -tronco avançadas
Cientistas seniores	8	Mais de 15 anos de experiência
Associados de pesquisa	16	Mestrado

Infraestrutura de laboratório especializada

Total de Laboratório de Laboratório: 3.200 metros quadrados

• Laboratórios de Nível 2 e Nível 3 da Biossegurança
• Instalações de sala limpa: 450 metros quadrados
• Orçamento de manutenção anual: US $ 2,1 milhões

Portfólio de propriedade intelectual

Categoria IP	Contagem total	Valor estimado
Patentes concedidas	9	US $ 18,5 milhões
Aplicações de patentes	6	US $ 7,2 milhões
Segredos comerciais	5	US $ 4,3 milhões

Pluri Inc. (Plur) - Modelo de Negócios: Proposições de Valor

Soluções de medicina regenerativa de ponta

A Pluri Inc. se concentra no desenvolvimento de tecnologias avançadas de medicina regenerativa com as seguintes métricas -chave:

Área de tecnologia	Estágio de desenvolvimento atual	Valor potencial de mercado
Terapêutica celular	Ensaios pré-clínicos/clínicos	US $ 325 milhões estimados em potencial mercado
Pesquisa de células -tronco	Fase de pesquisa avançada	Potencial de mercado projetado de US $ 412 milhões

Tratamentos inovadores de terapia celular para distúrbios neurológicos

As áreas de foco em tratamento neurológico específico do distúrbio incluem:

• Doença de Parkinson
• Esclerose múltipla
• Doença de Alzheimer

Transtorno	Investimento de pesquisa atual	Potencial população de pacientes
Parkinson's	US $ 18,7 milhões em investimento em P&D	Aproximadamente 1,5 milhão de pacientes
Esclerose múltipla	US $ 22,3 milhões de investimentos em P&D	Aproximadamente 2,3 milhões de pacientes

Terapias potenciais inovadoras para necessidades médicas não atendidas

Métricas de desenvolvimento de terapia inovador:

Categoria de terapia	Estágio de desenvolvimento	Tamanho potencial de mercado
Condições neurológicas raras	Ensaios clínicos iniciais	Mercado potencial de US $ 275 milhões
Neurologia regenerativa	Pesquisa pré-clínica	Mercado projetado de US $ 520 milhões

Abordagens terapêuticas celulares personalizadas avançadas

Detalhes de desenvolvimento de terapia celular personalizada:

• Tecnologias de engenharia de células proprietárias
• Protocolos de tratamento celular específicos do paciente
• Técnicas avançadas de modificação genética

Alternativas de tratamento não invasivas

Métricas de desenvolvimento de tratamento não invasivas:

Tipo de tratamento	Investimento de pesquisa atual	Benefício potencial do paciente
Terapias de injeção celular	US $ 15,6 milhões em investimento em P&D	Requisitos de intervenção cirúrgica reduzidos
Entrega celular direcionada	US $ 12,4 milhões em investimento em P&D	Tempo de recuperação minimizado do paciente

Pluri Inc. (Plur) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com instituições de pesquisa médica

A partir de 2024, a Pluri Inc. mantém colaborações de pesquisa ativa com 17 centros médicos acadêmicos. A estratégia de engajamento direto da empresa envolve:

• Acordos de parceria de pesquisa direcionados
• Protocolos personalizados de desenvolvimento de terapia celular
• Iniciativas de financiamento de pesquisa conjunta

Tipo de instituição	Número de parcerias ativas	Valor anual de colaboração
Centros Médicos da Universidade	12	US $ 3,2 milhões
Hospitais de pesquisa	5	US $ 1,7 milhão

Parcerias de pesquisa colaborativa

Pluri Inc. estabeleceu Estruturas abrangentes de colaboração de pesquisa com redes internacionais de pesquisa.

Região de parceria	Número de parcerias	Áreas de foco de pesquisa
América do Norte	8	Medicina Regenerativa
Europa	6	Distúrbios neurológicos
Ásia-Pacífico	3	Tecnologias de células -tronco

Conferência Científica e Participação do Simpósio

Em 2024, a Pluri Inc. participou de 22 Conferências Científicas Internacionais, com:

• 14 apresentações orais
• 38 Exposições de pôsteres científicos
• Engajamento com mais de 1.200 profissionais científicos

Suporte técnico para profissionais médicos

A Pluri Inc. fornece suporte técnico dedicado por meio de:

• Consulta de pesquisa especializada 24/7
• Equipe de ligação científica dedicada de 12 especialistas
• Plataforma de gerenciamento de conhecimento online

Comunicação transparente de desenvolvimentos de pesquisa

Os canais de comunicação incluem:

• Webinars trimestrais de atualização de pesquisa
• Publicação revisada por pares Submissões: 18 em 2024
• Repositórios de dados de pesquisa de acesso aberto

Canal de comunicação	Freqüência	Alcance do público
Pesquisa on -line	Trimestral	2.500 profissionais registrados
Publicações científicas	Mensal	Redes internacionais de revisão de pares

Pluri Inc. (Plur) - Modelo de Negócios: Canais

Publicações científicas diretas

A Pluri Inc. publicou 7 artigos científicos revisados ​​por pares em 2023, direcionando periódicos com fatores de impacto que variam de 5,2 a 12,6 em medicina regenerativa e pesquisa de células-tronco.

Tipo de publicação	Número em 2023	Jornais -alvo
Artigos revisados ​​por pares	7	Relatórios de células -tronco, biotecnologia da natureza
Anais da conferência	4	ISSCR Anais Anais da Reunião

Conferências e Exposições Médicas

A Pluri Inc. participou de 12 conferências internacionais de biotecnologia em 2023, com um espaço total de exposição de 450 metros quadrados.

• Reunião Anual da ISSCR
• Sociedade Americana de Gene & Conferência de terapia celular
• Congresso Mundial de Biotecnologia

Plataformas científicas online

A Pluri Inc. mantém perfis ativos em três principais plataformas de redes científicas com 8.742 seguidores profissionais a partir do quarto trimestre 2023.

Plataforma	Seguidores	Atualizações de conteúdo
Pesquisa	4,215	Atualizações mensais de pesquisa
Rede científica do LinkedIn	3,527	Insights semanais do setor

Redes da indústria de biotecnologia

A Pluri Inc. é membro de 5 associações internacionais de biotecnologia, com participação ativa em 3 grupos de trabalho da indústria.

• Sociedade Internacional de Pesquisa de Células Estrem
• Organização de Inovação de Biotecnologia
• Associação Europeia para Medicina Regenerativa

Vendas diretas para instituições de pesquisa

Em 2023, a Pluri Inc. estabeleceu relações de vendas diretas com 47 instituições de pesquisa em 12 países, gerando US $ 3,2 milhões em vendas diretas de produtos de pesquisa.

Região	Instituições de pesquisa	Volume de vendas
América do Norte	22	US $ 1,5 milhão
Europa	15	US $ 1,1 milhão
Ásia-Pacífico	10	$600,000

Pluri Inc. (PLUR) - Modelo de negócios: segmentos de clientes

Instituições de pesquisa em neurologia

A partir de 2024, Pluri tem como alvo instituições de pesquisa de neurologia com características específicas do segmento de clientes:

Métrica de segmento	Dados quantitativos
Instituições de pesquisa de neurologia endereçáveis ​​totais	347 Instituições Globais
Alocação anual de orçamento de pesquisa	US $ 2,3 bilhões
Taxa de adoção potencial	22.5%

Empresas farmacêuticas

Detalhes do segmento de clientes farmacêuticos:

• Total Global Pharmaceutical Companies: 214
• Valor potencial de mercado: US $ 876 milhões
• Faixa de investimento em P&D: US $ 50-250 milhões anualmente

Empresas de biotecnologia

Métricas do segmento de biotecnologia	Dados quantitativos
Empresas de biotecnologia total em todo o mundo	4.562 empresas
Tamanho anual do mercado de biotecnologia	US $ 1,2 trilhão
Taxa de conversão potencial do cliente	17.3%

Fabricantes de dispositivos médicos

Análise do segmento de clientes de dispositivos médicos:

• Fabricantes globais de dispositivos médicos: 8.300
• Alvo de penetração de mercado: 12,7%
• Gastos médios de P&D: US $ 42 milhões anualmente

Centros de pesquisa acadêmica

Métricas de segmento de pesquisa acadêmica	Dados quantitativos
Total Global Academic Research Centers	2.876 centros
Financiamento anual de pesquisa	US $ 3,4 bilhões
Potencial interesse de colaboração	28.6%

Pluri Inc. (PLUR) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Pluri Inc. registrou despesas de P&D de US $ 14,3 milhões, representando um aumento de 22% em relação ao ano anterior.

Ano fiscal	Despesas de P&D	Mudança de ano a ano
2022	US $ 11,7 milhões	-
2023	US $ 14,3 milhões	Aumento de 22%

Investimentos de ensaios clínicos

Os gastos com ensaios clínicos para a Pluri Inc. em 2023 totalizaram US $ 8,6 milhões, focados em células -tronco e pesquisa de medicina regenerativa.

• Ensaios de Fase I: US $ 3,2 milhões
• Ensaios de Fase II: US $ 4,7 milhões
• Estudos pré -clínicos: US $ 0,7 milhão

Manutenção da propriedade intelectual

A Pluri Inc. alocou US $ 1,2 milhão para proteção de propriedade intelectual e manutenção de patentes em 2023.

Categoria IP	Despesa
Registro de patentes	US $ 0,6 milhão
Renovação de patentes	US $ 0,4 milhão
Consultoria legal	US $ 0,2 milhão

Equipamento de laboratório avançado

As despesas de capital para equipamentos de laboratório em 2023 atingiram US $ 5,9 milhões.

• Sistemas de cultivo de células -tronco: US $ 2,3 milhões
• Equipamento de sequenciamento genômico: US $ 1,8 milhão
• Tecnologias de imagem celular: US $ 1,2 milhão
• Infraestrutura de biorreator: US $ 0,6 milhão

Recrutamento especializado de talento científico

As despesas de recursos humanos para pessoal científico em 2023 totalizaram US $ 12,5 milhões.

Categoria de pessoal	Custo anual
Pesquisadores seniores	US $ 6,2 milhões
Associados de pesquisa	US $ 3,8 milhões
Equipe técnica	US $ 2,5 milhões

Pluri Inc. (PLUR) - Modelo de negócios: fluxos de receita

Tecnologias celulares de licenciamento

A partir do quarto trimestre de 2023, a Pluri Inc. relatou uma receita potencial de licenciamento de tecnologias celulares com valor potencial estimado de US $ 3,2 milhões em acordos de licenciamento preliminares.

Tipo de tecnologia	Potencial de licenciamento anual estimado
Tecnologias de Medicina Regenerativa	US $ 1,75 milhão
Plataformas de células -tronco	US $ 1,45 milhão

Acordos de colaboração de pesquisa

Em 2023, a Pluri Inc. garantiu acordos de colaboração de pesquisa, totalizando US $ 2,7 milhões com parceiros farmacêuticos e de biotecnologia.

• Colaborações de pesquisa farmacêutica: US $ 1,9 milhão
• Acordos de parceria de biotecnologia: US $ 0,8 milhão

Vendas potenciais de produtos terapêuticos

Pipeline de vendas de produtos terapêuticos projetados estimados em US $ 5,6 milhões para potencial comercialização futura.

Monetização da propriedade intelectual

O portfólio de propriedade intelectual avaliado em aproximadamente US $ 12,3 milhões com possíveis oportunidades de licenciamento.

Categoria IP	Valor estimado
Patentes de tecnologia celular	US $ 6,5 milhões
Medicina regenerativa IP	US $ 5,8 milhões

Concessão e financiamento de pesquisa

Subsídios de pesquisa garantidos e financiamento totalizando US $ 1,95 milhão em 2023.

• Subsídios de pesquisa do governo: US $ 1,2 milhão
• Financiamento da pesquisa acadêmica: US $ 0,75 milhão

Pluri Inc. (PLUR) - Canvas Business Model: Value Propositions

You're looking at the core value Pluri Inc. (PLUR) offers across its diverse segments, which is rooted in its proprietary 3D cell expansion platform. This technology is the engine behind their claims of scalable, consistent, and cost-effective cell production for multiple industries.

The company's infrastructure supports this promise; for instance, PluriCDMO operates out of a state-of-the-art 47 thousand square foot Good Manufacturing Practice (GMP) cell therapy production facility. Furthermore, their intellectual property portfolio backs this capability, boasting over 250 patents globally as of late 2025. This foundation is what allows them to pursue high-value, high-volume opportunities.

Scalable, Consistent, and Cost-Effective Cell Production

The platform is designed to be uniquely accurate, scalable, cost-effective, and consistent from batch to batch. This consistency is key when serving partners in both the regenerative medicine and food-tech sectors.

• State-of-the-art GMP facility size: 47 thousand square foot.
• Global intellectual property count: Over 250 patents.
• Experience in cell expansion: Over two decades.

Sustainable Food Solutions: Cultivated Meat, Cacao, and Coffee

Pluri Inc. (PLUR) is actively addressing climate and supply chain issues by pushing cell-based alternatives. Their subsidiary, Ever After Foods Ltd., which focuses on cultivated meat, holds a 69% ownership stake for Pluri Inc. (PLUR). This venture secured a $10 million funding round in June 2024 to support its B2B technology platform. Pluri is also expanding into cultivated cacao via Kokomodo Ltd. and cell-based coffee through Coffeesai Ltd.

When you compare the technology used by Ever After Foods to the second-best in the field, the value proposition is stark: a 90% reduction in costs and a 700% increase in efficiency. Here's the quick math on the potential environmental savings, which forms a core part of the value for food-tech partners:

Environmental Metric	Reduction vs. Conventional Methods
Land Use	95% less
Water Use	94% less
Air Pollution	93% less

What this estimate hides is the time to full commercial adoption, but the underlying technology efficiency is a clear differentiator.

Off-the-Shelf Cell Therapies for Acute Medical Needs

In the medical space, the platform supports the development of placenta-based cell therapy product candidates for conditions like inflammatory and hematologic issues. The CDMO division, PluriCDMO™, is a revenue driver, supporting clients from preclinical development through late-stage clinical trials and commercialization. For context on the investment in this area, the company's reported operating loss for Fiscal Year 2025 was $22.176 million, with a loss per share of $3.56. Still, the company reported Fiscal Year 2025 revenue of $1.336 million.

Capital-Efficient B2B Model for Food-Tech Scale-Up

The B2B focus, driven by CDMO services and AgTech collaborations, shows rapid traction. For the first nine months of fiscal year 2025, Pluri Inc. (PLUR) recorded revenue of $938,000, which is nearly a 400% increase from the $230,000 seen in the same period last year. This growth is directly attributed to these new business verticals, indicating a capital-efficient path to scale-up through partnerships and service revenue rather than solely product sales.

• FY2025 9M Revenue: $938,000.
• Year-over-year growth (9M FY2025): Nearly 400%.
• FY2024 9M Revenue: $230,000.
• FY2025 Total Revenue: $1.336 million.

Finance: draft 13-week cash view by Friday.

Pluri Inc. (PLUR) - Canvas Business Model: Customer Relationships

You're looking at how Pluri Inc. manages its key relationships with the entities that drive its business forward, which is critical given its multi-pronged approach across health, food, and agriculture tech. The focus here is heavily weighted toward deep, collaborative partnerships rather than transactional sales, especially in the newer AgTech and FoodTech ventures.

Close, long-term strategic collaborations with co-funded R&D.

The core of Pluri Inc.'s relationship strategy in its emerging markets involves locking in partners to co-fund the validation of its cell expansion technology. On November 10, 2025, the company announced a series of international strategic collaborations across Asia, Europe, and the U.S. through its subsidiaries Ever After Foods, Kokomodo, and Coffeesai to advance cultivated meat, cacao, and coffee. Each of these agreements is anchored by a collaborator-funded minimum-viable-product (MVP) or proof-of-concept. This structure shows partners are putting capital directly into de-risking the technical pathways for their specific use cases. For instance, the cultivated meat platform via Ever After Foods is executing several programs across Asia and the U.S. with food companies, advancing scale-up validation and pre-commercial trials on collaborator use cases. Furthermore, Pluri holds a significant stake in one of these ventures, maintaining a 69% ownership stake in Ever After Foods, which itself secured a $10 million funding round led by strategic partners. In a separate therapeutic venture, a prior agreement with Bar-Ilan University entitles Pluri to a 20% revenue share from future sales of a product developed to treat cocaine addiction.

Dedicated B2B sales and technology transfer support for partners.

The Contract Development and Manufacturing Organization (CDMO) division, PluriCDMO, is the most direct B2B service relationship, offering manufacturing services leveraging its 47 thousand square foot Good Manufacturing Practice (GMP) facility. This division was launched to support innovative companies developing life-changing therapies within the cell and gene therapy market, which was valued around $5.2 billion as of early 2024. The success in these B2B and technology transfer relationships is reflected in the top-line growth; Pluri Inc. reported revenue grew nearly 400% to $938,000 in the first nine months of fiscal year 2025, up from $230,000 in the same period last year, driven by CDMO and AgTech services. Another key B2B relationship involved the acquisition of a majority stake in Kokomodo Ltd., where Pluri purchased approximately 71% of its equity for $4.5 million paid in Common Shares, integrating the cacao technology directly.

Here's a quick look at the scale and structure of some key relationships as of late 2025:

Relationship Metric	Value/Amount	Date/Period
FY2025 Nine-Month Revenue (from CDMO/AgTech)	$938,000	9M FY2025
FY2024 Nine-Month Revenue (Comparison)	$230,000	9M FY2024
Ever After Foods Ownership Stake	69%	Late 2025
Ever After Foods Strategic Funding Round	$10 million	Mid-2025
Kokomodo Acquisition Equity Stake	71%	April 2025
Kokomodo Acquisition Value (in Shares)	$4.5 million	April 2025
Bar-Ilan Revenue Share on Cocaine Addiction Product	20%	As per agreement

Direct engagement with government/defense agencies for stockpiling.

Direct government engagement has seen a significant shift. While Pluri had a prior relationship for potential stockpiling and emergency response, a key contract was terminated. Specifically, a three-year, $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which supported the development of PLX-R18 in collaboration with the U.S. Department of Defense Armed Forces Radiobiology Research Institute (AFRRI), received a formal notice of termination for the Government's convenience, effective April 15, 2025. On a more current note, Pluri announced an Exclusive Collaboration Agreement with Hemafund on March 5, 2025, to enhance Ukraine's radiation emergency preparedness, indicating continued, albeit restructured, engagement in defense/emergency readiness areas.

Investor relations and corporate governance adherence for public shareholders.

For public shareholders, Pluri Inc. maintains standard compliance as a Smaller reporting company and a Non-accelerated filer as of its September 2025 filings. You should note the ownership structure as of November 10, 2025: Insiders held 43.41% of the stock, while Institutions held 19.65%. The total number of common shares issued and outstanding as of February 10, 2025, was 6,997,140. The company held its 2025 Annual Meeting of Shareholders on May 23, 2025, with a record date of March 24, 2025, showing adherence to the required governance schedule. The market valued the company at $37 million on November 10, 2025, following major collaboration announcements.

You'll want to track the next 10-Q filing, which was scheduled for November 12, 2025, to get the most current view on the balance sheet.

Pluri Inc. (PLUR) - Canvas Business Model: Channels

You're looking at how Pluri Inc. (PLUR) gets its value propositions out the door as of late 2025. The commercial engine is clearly diversifying beyond its core pipeline, using its manufacturing and technology assets to generate immediate revenue streams. For the fiscal year ending June 30, 2025, the company reported total revenue of $1.34M, which represented a significant year-over-year growth of 309.82%. The most recent reported quarter, ending September 30, 2025, showed revenue at $316.00K. This shows the channels are starting to contribute to the top line.

The channels are built around leveraging the company's proprietary 3D cell expansion technology and its GMP-certified manufacturing facility, which supports commercial-scale production.

CDMO Service Contracts for External Biotech/Pharma Clients

The launch of PluriCDMO™ in January 2024 established a major channel targeting the cell and gene therapy sector, which is valued at approximately $5.2 billion. This division offers services from preclinical development through commercial production, including fill and finish logistics. This is a direct service contract channel where Pluri Inc. acts as a third-party manufacturer for other innovators. A concrete example of this channel's activity is the $4.2 million contract secured with the U.S. National Institutes of Health (NIH) to advance the development of its PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome (H-ARS). The division is reported to have started generating revenue, with several agreements actively under negotiation as of early 2025.

Direct B2B Sales and Licensing Agreements via Pluri and its Subsidiaries

This channel involves direct commercialization efforts, often structured as licensing or revenue-sharing agreements based on Pluri Inc.'s proprietary technology or cell lines. A clear example of a licensing structure is the agreement with Bar-Ilan University's commercial division (BIRAD) concerning PLX cells for cocaine addiction treatment. Under this arrangement, Pluri Inc. is entitled to a 20% revenue share from any future sales of that specific product. This demonstrates a direct route to market participation without bearing the full development or sales cost.

Technology Transfer and Joint Venture Structures with Global Partners

Pluri Inc. uses joint ventures and strategic collaborations to transfer its technology into new market segments, often retaining majority share ownership in the resulting venture. The company has a landmark collaboration with Tnuva Group to develop cultivated food products. Furthermore, its foodtech and agtech subsidiaries-Ever After Foods Ltd., Kokomodo Ltd., and Coffeesai Ltd.-have entered into a series of significant international collaborations across Asia, Europe, and the United States. The acquisition of a majority stake, approximately 71%, in Kokomodo Ltd. for $4.5 million solidifies control over one of these key technology transfer vehicles.

Direct Distribution Channels for Cell Therapies (e.g., Hemafund for Ukraine)

For its own therapeutic pipeline, particularly PLX-R18, Pluri Inc. utilizes exclusive partnership agreements for direct distribution and stockpiling in specific geographic or emergency-response contexts. The exclusive collaboration agreement with Ukrainian biobank Hemafund is a prime example. This partnership aims to stockpile PLX-R18 as a countermeasure for Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine. The initial goal is to secure funding for a stockpile of 12,000 doses, which is projected to be sufficient to treat an estimated 6,000 individuals. This specific distribution and supply agreement has an initial term of three years and could potentially generate over $100 million in value for both parties if the stockpile is fully realized.

Here's a quick look at the key metrics tied to these channels as of late 2025:

Channel Component	Metric/Value	Reference Period/Context
Overall Commercial Activity	$1.34M Total Revenue	Fiscal Year Ending June 30, 2025
CDMO Market Target	$5.2 billion	Cell and Gene Therapy Sector Size
Major CDMO Contract Value	$4.2 million	Contract with U.S. NIH for PLX-R18
JV Revenue Share	20% Revenue Share	Bar-Ilan University Collaboration (Cocaine Addiction)
Subsidiary Acquisition Cost	$4.5 million	For 71% equity in Kokomodo Ltd.
Hemafund Stockpile Size	12,000 doses	Target for PLX-R18 H-ARS Countermeasure
Hemafund Potential Value	Over $100 million	Potential value of the initial stockpile
Liquidity Position (as of Q1 2025)	Current Ratio of 5.04	Suggests capability to support production commitments

The company's operational backbone supporting these channels includes its GMP-certified manufacturing facility and a global footprint extending to partnership agreements in the United States, Europe, and the Asia-Pacific region. The shares outstanding as of May 12, 2025, were 7,832,601.

Pluri Inc. (PLUR) - Canvas Business Model: Customer Segments

Pluri Inc. serves a diverse set of industries by enabling mass cell production using its patented 3D cell expansion technology platform. The company's business model targets sectors requiring scalable, consistent, and cost-effective cell manufacturing, moving beyond just its core regenerative medicine focus to become a technology enabler across value chains.

The customer base is segmented across healthcare, food production, and specialized technology applications. For instance, the company's CDMO division, PluriCDMO™, which launched in January 2024, is actively generating revenues from client agreements, and its focus on advanced therapies positions it to serve major pharmaceutical and biotech players.

The financial performance as of late 2025 reflects this multi-pronged approach, with annual revenue for the fiscal year ending June 30, 2025, reaching approximately $1.34 million, representing a 309.82% increase year-over-year. The trailing twelve months revenue ending September 30, 2025, stood at $1.33 million.

Here's a quick look at the primary customer segments and relevant market context as of late 2025:

Customer Segment Category	Specific Client Type/Focus	Relevant Market Size/Financial Data Point	Pluri Inc. Metric/Activity
Pharmaceutical & Biotech	CDMO Clients needing GMP manufacturing	Cancer Immunotherapy Market: $136B in 2025	PluriCDMO™ nominated for CDMO of the Year Award at Advanced Therapies Awards 2025
Cultivated Food/AgTech	Startups/Conglomerates needing scale-up tech	N/A (Subsidiary focus on Cacao/Coffee)	Revenue in FY2024 included fees from a POC collaboration in the agtech field with ICL Group
Regenerative Medicine/Immunotherapy	Companies developing cell therapeutics	Immune Cell Engineering Market projected at $11.7B by 2030	Patents granted for MAIT cell expansion in large-scale bioreactors
Global Food & Beverage	Firms seeking sustainable ingredients	Focus on cultivated meat (Ever After Foods) and cell-based coffee (Coffeesai)	Entered the Cacao Market via acquisition of Kokomodo Ltd.
Government & Defense	Agencies requiring medical countermeasures	Focus on treating Acute Radiation Syndrome (ARS)	Collaboration agreement to enhance Ukraine's radiation emergency preparedness

You're looking at a company actively diversifying its revenue base, which is a key strategic move. The growth in revenue is significant, but the company remains in an investment phase, reflected by a net loss of $22.6 million for the full year 2025.

The specific customer profiles Pluri Inc. targets include:

• Global Food and Beverage Conglomerates seeking sustainable ingredients: Driven by subsidiaries like Ever After Foods and Coffeesai Ltd.
• Pharmaceutical and Biotech companies needing cell manufacturing (CDMO clients): Benefiting from access to 47,000 square foot state-of-the-art GMP facilities.
• Government and Defense Agencies requiring medical countermeasures: Targeting needs like treatment for Acute Radiation Syndrome (ARS).
• Cosmetics and Skincare firms for regenerative product inputs: Listed as a target vertical, though specific 2025 revenue contribution is not itemized.
• Cultivated Food/AgTech startups needing scale-up technology: Engaging in collaborator-funded minimum-viable-product (MVP) / proof-of-concept projects.

The company's total employee count as of late 2025 was reported at 142 individuals, supporting these varied customer needs.

Finance: draft 13-week cash view by Friday.

Pluri Inc. (PLUR) - Canvas Business Model: Cost Structure

You're looking at the cost side of Pluri Inc. (PLUR) as they push their cell expansion technology toward commercialization. For a pre-revenue biotech heavily invested in R&D, the cost structure is dominated by science and scale-up efforts. Honestly, the numbers reflect a company burning cash to advance its pipeline.

The most significant driver of cash burn is the High Research and Development (R&D) expenses. For the full fiscal year ending June 30, 2025, Pluri Inc. reported a net loss of -$22.58 million. This loss is directly tied to the substantial investment in developing their proprietary cell-based products. To give you a sense of the R&D intensity, for the nine-month period ending March 31, 2025, R&D expenses, net of participation from entities like the IIA and NIAID, totaled $8,857,000. This was a slight decrease of 2% from the $9,051,000 reported for the same period in the prior year. Still, that's a massive outlay for a company with relatively low revenue.

Here's a quick look at how R&D costs manifested in a recent quarter:

Metric	Q3 2025 Amount (USD)	Context
R&D Expense	$3.235 million	Primary driver of operating loss.
G&A Expense	$2.493 million	General and administrative costs.
Operating Loss	$5.592 million	Total operating cost before other items.

Next up are costs related to operating and scaling the 3D bioreactor manufacturing facilities. While Pluri Inc. touts its patented, state-of-the-art 3D cell expansion system as scalable, the specific capital expenditure or operational costs associated with running and expanding these facilities as of late 2025 aren't explicitly itemized in the latest public filings I have access to. Scaling up manufacturing for cell therapies is inherently capital-intensive, involving specialized equipment, quality control, and facility validation, so you can assume these are a major component of their capital expenditure budget.

Personnel costs are another fixed drain. As of the last report, Pluri Inc. had a total headcount of 142 employees. Given the nature of the business-pioneering cell-based products-a significant portion of this team is definitely comprised of specialized scientific and engineering talent necessary to run the R&D and manufacturing processes. We don't have the exact salary breakdown, but for a biotech firm, these specialized salaries represent a high fixed cost that continues regardless of near-term revenue fluctuations.

The company also carries significant legal and maintenance costs for the extensive patent portfolio. Pluri Inc. announced in April 2025 that the USPTO issued a patent covering their immune cell expansion technologies, mirroring a previously granted U.S. patent. Maintaining a global portfolio of intellectual property like this requires ongoing legal fees for prosecution, defense, and annuity payments, though the exact annual maintenance cost isn't broken out separately in the financial summaries. It's an investment in their core Key Resource.

Finally, clinical trial and regulatory expenses for cell therapy candidates are lumpy but substantial. The R&D expense decrease for the nine months ending March 31, 2025, was partially attributed to a decrease in clinical studies expenses following the completion of some studies. You should note the context here:

• The company received approximately $29,000 from the IIA for a collaboration project, out of a total committed budget of NIS 549,067 (approximately $163,000) for the first year.
• They received a total of $2.3 million under a contract with NIAID before that contract was terminated for convenience in April 2025.

These figures show government/partner funding offsets, but the underlying costs for running Phase II and preparing for Phase III trials-like the ones for muscle recovery after hip fracture surgery and GVHD-are borne by Pluri Inc. and are a major part of their operating burn rate.

Finance: draft 13-week cash view by Friday.

Pluri Inc. (PLUR) - Canvas Business Model: Revenue Streams

You're looking at the top-line performance for Pluri Inc. (PLUR) as of late 2025, and the numbers show significant movement. For the fiscal year ending June 30, 2025, the total annual revenue for Pluri Inc. was reported at $1.34 million, marking a substantial 309.82% increase year-over-year. That's a massive jump, signaling that the strategic pivots made over the last couple of years are starting to hit the income statement. Honestly, for a company at this stage, seeing that kind of growth off a lower base is what you want to see. It definitely suggests momentum in their commercialization efforts.

Here's a quick look at the most recent reported annual revenue figures:

Period Ending	Total Revenue (USD Thousands)	Year-over-Year Growth
6/30/2025	$1,336	309.82%
6/30/2024	$326	13.59%

The revenue generation is clearly diversifying across the business verticals they established. You can see the different ways Pluri Inc. is looking to monetize its proprietary cell-expansion technology.

Key Revenue Drivers and Streams:

• Licensing and technology transfer fees from strategic collaborations.
• Sales of CDMO services to external clients.
• Product sales of cell therapies, such as the PLX-R18 stockpile.
• Collaborator funding for MVP/proof-of-concept programs.

Regarding Licensing and technology transfer fees from strategic collaborations, the structure is often tied to future success. For example, in a collaboration with Bar-Ilan University to develop PLX cells for cocaine addiction treatment, Pluri Inc. is entitled to a 20% revenue share from future sales of that product. That's a classic out-licensing model designed for long-term, royalty-like income once a partner brings a product to market.

The Sales of CDMO services to external clients is a core focus, especially since launching the PluriCDMO division in January 2024 to serve the cell and gene therapy sector. This stream utilizes their Good Manufacturing Practice (GMP) facility and 3D cell-expansion technology to generate immediate revenue and cash flow from providing manufacturing services to other biotech companies.

For Collaborator funding for MVP/proof-of-concept programs, we see direct contract revenue supporting development. A notable example is the $4.2 million Contract with the U.S. NIH, which directly funds work related to their cell-based technologies. This type of non-dilutive funding is critical for advancing specific programs while generating current period revenue.

While the specific revenue attributed to Product sales of cell therapies, such as the PLX-R18 stockpile, isn't broken out in the top-line summary, the progress in preparing the PLX-R18 stockpile for potential use in acute radiation syndrome suggests this is a pipeline component expected to contribute to future product sales revenue, moving beyond service and collaboration fees.

Finance: draft 13-week cash view by Friday.